![]() | |
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a693021 |
Routes of administration | Intravenous, intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 29% |
Elimination half-life | 0.65–1.20 hrs |
Excretion | Mainly kidneys (41–66% within 8 hrs) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.063.506 |
Chemical and physical data | |
Formula | C8H11NO5S |
Molar mass | 233.24 g·mol−1 |
3D model (JSmol) | |
Melting point | 148 to 151 °C (298 to 304 °F) |
| |
| |
(verify) |
Sulbactam is a β-lactamase inhibitor. This drug is given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics. [1]
It was patented in 1977 and approved for medical use in 1986. [2]
The combination ampicillin/sulbactam (Unasyn) is available in the United States. [3]
The combination cefoperazone/sulbactam (Sulperazon) is available in many countries but not in the United States. [4]
The co-packaged combination sulbactam/durlobactam was approved for medical use in the United States in May 2023. [5]
Sulbactam is primarily used as a suicide inhibitor of β-lactamase, shielding more potent beta-lactams such as ampicillin. [6] Sulbactam itself contains a beta-lactam ring, and has weak antibacterial activity by inhibiting penicillin binding proteins (PBP) 1 and 3, but not 2. [7]